Skip to main content

Table 2 Results of human magnetic luminex assay

From: Coronary microvascular dysfunction is associated with degree of anaemia in end‐stage renal disease

Assay CFVR < 2 (n = 6) CFVR ≥ 2 (n = 15) p value
Angiopoetin-2 (pg/ml) 3274 (1000–5136) 3051 (2230–4053) 0.850
Atrial natriuretic peptide (pg/ml) 25,836 ± 9520 20,568 ± 11,210 0.329
Detectable KIM-1 n (%) 2 (33) 5 (31) 1.0
Galectin-3 (ng/ml) 1.3 (1-1.3) 1.3 (1-1.4) 0.791
IL-1ra (pg/ml) 667 (526–742) 515 (384–729) 0.850
IL-6 (pg/ml) 2.09 ± 1.3 2.69 ± 1.35 0.371
IL-8 (pg/ml) 6.1 (4.2–11.5) 11.4 (8–23) 0.132
IL-10 (pg/ml) 2.5 (0.9–4.1) 1.4 (0.9–3.4) 1.0
Leptin (ng/ml) 17.7 (6.6–20.6) 13.2 (4.2–50.4) 0.910
MCP-1 (pg/ml) 396 ± 221 375 ± 102 0.770
MMP-9 (pg/ml) 10,614 (4955–11,509) 9880 (6244–13,648) 1.0
NGAL (ng/ml) 26.3 ± 8.9 26.6 ± 4.8 0.898
ST2 (ng/ml) 14 (10–33) 12 (9–19) 0.850
TNF\({\upalpha }\) (pg/ml) 6.1 (4.5–8.1) 5.7 (5.1–6.7) 0.850
Uromodulin (ng/ml) 18 ± 9 21 ± 10 0.53
VEGF (pg/ml) 52 ± 26 75 ± 25 0.108
  1. Data are presented as mean ± SD or median (IQR)
  2. CFVR, coronary flow velocity reserve; KIM-1, kidney injury molecule 1; IL-1ra, interleukin 1 receptor antagonist; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein; MMP-9, matrix metallopeptidase 9; NGAL, neutrophil gelatinase associated lipocalin; ST2, suppression of tumorigenicity 2; TNFα, tumour necrosis factor alpha; VEGF, vascular endothelial growth factor.